Clinical Trial Update: Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating ficerafusp alfa with pembrolizumab in resectable head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Ficerafusp Alfa (ficerafusp alfa)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: RECRUITING